In the News Please note that to read the full articles you will need Adobe Acrobat Reader 5.0+ plugin. You can download a free copy of Adobe Acrobat Reader by clicking here.

Genepharm, Strides merger moves closer
BioTechnologyNews.net, 1/5/2008.

THE proposed merger between Genepharm Australasia and Indian over-the-counter and generic manufacturer Strides Arcolab has moved a step closer with the signing of a share purchase agreement. (Read full PDF)

Deal is a sugar-coated pill
Herald Sun, 12/2/2008.

(Read full PDF)

Criterion with Tim Boreham
The Australian, 21/9/2007.

OSTENSIBLY the generic drug game holds little investor appeal given the Government has ordered suppliers to charge 25 per cent less next year. But Genepharm chief Dennis Bastas says that folk have wrongly assumed that if market leader Sigma is doing it tough, others must be doing it even harder. (Read full PDF)

Wrong take on tablets
Herald Sun, 19/9/2007.

DENNIS Bastas is out to prove the critics wrong. The head of listed generic drug company Genepharm thinks the market has entirely misread the looming 25 per cent cut in the wholesale price of generic drugs. (Read full PDF)

Genepharm in the red.
The Age, 29/8/2007.

GENERIC pharmaceuticals company Genepharm Australasia has posted a full-year loss, after a multi-million dollar write-down. (Read full PDF)

Genepharm shares rocket despite $18 million loss.
AAP Newswire, Tuesday 28/8/2007.

Shares in Genepharm Australasia Ltd rose by 35 per cent this morning, despite the generic pharmaceuticals maker posting an annual net loss of $18 million. (Read full PDF)

Chemical mix.
Herald Sun, 20/6/2007.

GENERAL manager of the My Chemist and Chemist Warehouse chain of pharmacies, Michael Story, joins Genepharm Australasia as chief operations officer from July 1. (Read full PDF)

Genepharm becoming brand conscious.
Financial Review, 30/11/2006.

Generic pharmaceuticals company Genepharm Australasia might spend up to $100 million on acquisitions next year as it seeks to become a diversified health business with a portfolio of prescription and over the counter drugs and vitamins. (Read full PDF)

Genepharm seeks more acquisitions.
The Australian, 30/11/2006.

GENEPHARM'S board is looking to make more acquisitions as it announced positive cash flow for the first time and suggested a dividend return by 2008 at its annual general meeting yesterday. (Read full PDF)

Health care's prescription is M&A.
Financial Review, 27/11/2006.

The nation's health-care services sector is ripe for consolidation and expect some big moves over the next year or so as boardrooms take advantage of the massive cost savings expected to flow from mergers and acquisitions. (Read full PDF)

Drugs reform a bitter pill to swallow.
Financial Review, 22/11/2006.

New rules will cut the price of products, affecting earnings of the big players reports Flona Tyndall. (Read full PDF)

Reaffirmed as a long-term buy.
The Australian, 16/9/2006.

Reaffirmed as a long-term buy. (Read full PDF)

Genepharm (GAA) 97.5c
The Australian, 12 September 2006.

Genepharm yesterday reported a better than expected $3.57 million loss in EBITDA terms, which didn't include any contribution from Genepharm's $70 million purchase of the local arm of Douglas Pharmaceuticals. (Read full PDF)

Genepharm basks in ABN embrace and Tassie tender.
The Financial Review, 20 July 2006.

The health-care sector has mainly been a source of disappointment of late, but one up-and-comer is Genepharm Australasia, the generic drugs group that recently paid $70 million for Douglas Pharmaceuticals to become the third biggest player behind Alphapharm and Sigma. (Read full PDF)

Genepharm ready for dose of real stuff.
The Financial Review, 28 June 2006.

The health services sector is traditionally viewed as a safe haven when markets are unstable, but in the past month the larger health services companies have been hit just as hard as the market generally. At the same time, however, some value appears to be emerging in small-cap health stocks such as Genepharm. (Read full PDF)

Drug distributor starts to make a name for itself.
The Age, 12 June 2006.

Generic drug distributor Genepharm Australasia has agreed to pay $70 million for another generic drug outfit (Read full PDF)

Genepharm (GAA) $1.08
The Australian, 7 June 2006.

The generic drugs minnow can hardly be accused of timidity as it moves into the big league through its $70 million scrip acquisition of the local arm of Douglas Pharmaceuticals. (Read full PDF)

Generics to cure PBS cost headache.
The Financial Review, 30 May 2006.

Generic medicines manufacturer Genepharm Australasia is seeking to raise $60 million to fund the acquisition of a local pharmaceutical business enabling it to grab a bigger slice of the nation's $1 billion generics market. (Read full PDF)

Inside Business.
ABC, 21 May 2006.

The nation's pharmacists and drug companies no doubt felt like reaching for their headache pills this week when news leaked out about the government's plans to pull $1 billion out of the Pharmaceutical Benefits Scheme. (Play Video Clip)  32MB  requires Windows Media Player

Biotech on high.
The Herald Sun, 2 February 2006.

Shares in local biotech Genepharm Australasia soared more than 13 per cent yesterday after receiving approval to sell its own version of the nation's top-selling anti-cholesterol drug. (Read full PDF)

Cholesterol drug OK opens cash artery for Genepharm.
The Age, 2 February 2006.

Generic drug maker Genepharm will be able to sell its own version of lucrative cholesterol treatment Simvastatin from April. (Read full PDF)

Genepharm Australasia (GAA) 94c.
The Australian, 14 December 2005.

The generic drugs hopeful has talked the talk since listing in June last year, but is now entering the action zone with its ambitions to become the third force in the $1billion-plus generics sector. (Read full PDF)

Biotechs get bang from new drugs.
Financial Review, 14 September 2005.

Generics will boom as governments look for cheaper forms of drugs. . . Genepharm Australasia is developing generic drugs for the pharmaceutical industry and has a market capitalisation of $75 million. (Read full PDF)

Watch Genepharm Australasia, ABN Says.
Australasian Investment Review, 12 September 2005.

ABN Amro Morgans has upgraded Genepharm Australasia (GAA) to Buy from Add in anticipation of the company registering its first generic products. (Read full PDF)

The Best Medicine.
The Daily Telegraph, 10 September 2005.

Generic pharmaceutical company Genepharm yesterday issued its annual profit showing a net cash outflow of $2.244 million and a $1.253 million loss. GAA directors said this showed the cash position was ahead of budget and it was on track for GAA's first pharmacy (sales) in the second half of this fiscal year. GAA shares jumped 8c to 96c. (Read full PDF)

Genepharm has appealing generic drugs story to sell.
Financial Review, 12 July 2005.

Investors and governments are getting increasingly excited about generic pharmaceuticals. Taking advantage of the popularity surrounding the supply of low-cost drugs to an ageing population is the Chief Executive and CFO of Genepharm Australasia. (Read full PDF)

Market Watch - Genepharm Interview.
CNBC Asia, 12 July 2005.

The generic drug sector is set to boom downunder. Analysts predict the sector will grow as the government seeks cheaper drugs for the country's ageing population. (Play Video Clip)  16MB  requires Windows Media Player

Generic drug dealers to pharmaceutically benefit.
Australasian Investment Review, 7 July 2005.

The ageing population and increasing consumer demand for affordable medicine is placing pressure on the Pharmaceutical Benefits Scheme (PBS), reports ABN Amro Morgans. According to the latest data, the Commonwealth paid $5.4bn in PBS benefits in 2004, up 11% on the previous year. (Read full PDF)

Genepharm firms up launch timing.
Pharma in Focus, 4 July 2005.

Having announced distribution deals with Sigma, API and Mayne last week, new generics player Genepharm says it anticipates launching 18 products into the Australian market next year. (Read full PDF)

Genepharm strikes deals.
The Age, 28 June 2005.

Genepharm Australasia Ltd has entered into deals with major pharmacy wholesale distributors Mayne Group, Sigma Co and API to distribute its generic pharmaceuticals. (Read full PDF)

Genepharm's generic genies anticipate "very sexy sector" .
The Age, 17 May 2005.

Genepharm is on the verge of announcing the details of its much-anticipated retail pharmacy distribution plan and betting types are suggesting the generic drug maker will sign multiple deals with all three distributors. (Read full PDF)

Good Medicine.
Seven Network, 19 April 2005.

Australian patients are set to save millions on prescriptions for some of the world's best selling super drugs. (Play Video Clip)  3.5MB  requires Windows Media

Player Generic Drug Frenzy.
BRW, 24 March 2005.

With patents expiring, ageing populations and increasing pressure from government and consumers to curb health costs, the use of generic drugs around the world is accelerating. (Read full PDF)  850kB

The Ups and Downs of Biotechs.
Independent Weekly, 30 January 2005.

The best return for the year was received by those who invested in Genepharm Australasia, which delivered an impressive gain of 176 per cent over its listing price of 50 cents. (Read full PDF)

Same Year, Different Colours.
Australasian Investment Review, 12 January 2005.

2004 was a vintage year with smaller caps outperforming domestic large caps already running on steroids. Or was it? As it turns out, investors' views on 2004 very much depend on their framework for the year. (Read full PDF)

Top Picks For 2005.
Australasian Investment Review, 12 January 2005.

Every method of stock pickings has its disadvantages and limits, with ABN Amro Morgans' Top Picks for 2004 generating a return of 29% for the year to November 30. (Read full PDF)

2004 may smash IPO records: Deloitte.
The Age, 3 December 2004.

A surge of stockmarket floats in December is set to boost the number of public offers of shares (IPOs) in 2004, up by 73 per cent on last year. On the back of record-smashing sharemarket indices, there will be an unprecedented 176 IPOs in 2004, raising $10.4 billion. (Read full PDF)

Brief case - Genepharm Australasia Limited.
The Age, 2 December 2004.

Imitation is said to be the sincerest form of flattery, but few pharmaceutical manufacturers are pleased about rivals legally copying their drugs. Genepharm Australasia fits into the imitator category, which also includes market leader Alphapharm, Arrow and Sigma. (Read full PDF)

Generic medicine big business.
The Australian Senior, December 2004.

The cost of cholesterol-reducing drug Simvastatin will become cheaper when it comes off patent in July next year. Generic medicines pharmaceutical company Genepharm is currently seeking registration of its substitute product with the Therapeutic Goods Administration. (Read full PDF)

Biotech Business Report.
Sky News, 26 November 2004.

Bio-tech companies represent only 3% of ASX but they capture plenty of attention with their blue sky potential. The Securities Institute of Australia has brought together several Australian pharmaceutical research companies. (Play Video Clip) 2.5MB requires Windows Media Player

Generic drug makers will give investors a nice high.
Financial Review, 1 November 2004.

The generic pharmaceutical sector is coming under closer investor scrutiny as the giants of the industry, such as GlaxoSmithKline, Pfizer and Novartis start to consider a future in which they don't have their protected patent status. (Read full PDF)

Selling the pharm.
Herald Sun, 16 September 2004.

Pharmaceuticals company Genepharm Australasia has appointed Keith Jeffs as its new director of sales and marketing. (Read full PDF)

Fever Symptoms.
BRW, 2 September 2004.

An avalanche of big-selling drugs will come off patent during the next few years, leaving generic drug business poised for a period of strong growth. The prospect has already produced steep increases in the shares of the two listed specialist generic drug companies, Arrow Pharmaceuticals and Genepharm Australasia. (Read full PDF)

Genepharm submits drugs to TGA.
The Age, 20 August 2004.

Generic medicines firm Genepharm Australasia has submitted five generic anti-cancer drugs for registration with the Therapeutic Goods Administration (TGA). The estimated cost to Australia's Pharmaceutical Benefits Scheme (PBS) for these five drugs is $30-40 million annually. (Read full PDF)

Genepharm debut stirs Sigma's interest in generics.
The Australian, 11 June 2004.

Pharmaceuticals Drug manufacturer Sigma yesterday flagged a possible move into the burgeoning market for generic pharmaceuticals, as new sector entrant Genepharm made a stellar stock exchange debut. (Read full PDF)

Generic druggist breaks float lull.
The Age, 11 June 2004.

Generic drug company Genepharm Australasia yesterday broke the mould of subdued stock exchange listings, arriving on the boards at a 16¢ premium to its 50¢ issue price. (Read full PDF)

Greek drug maker makes a healthy beginning.
Financial Review, 11 June 2004.

Privately owned Greek pharmaceuticals giant Genepharm's aim to capture a bigger slice of Australia's fast-growing generic drugs market moved a step closer yesterday when shares in the company's local unit started trading at a premium of more than 30 per cent to their issue price. (Read full PDF)

Pharmaceutical group gives stags a good gain.
SMH, 11 June 2004.

Generic drug distributor Genepharm yesterday broke the mould of subdued stock exchange listings, arriving on the boards at a 32 per cent premium to it's issue price. (Read full PDF)

Genepharm makes healthy debut.
AAP, 10 June 2004.

Generic pharmaceutical company Genepharm Australasia Ltd made a healthy debut on the stock exchange, opening at a 16 cent premium to its issue price. (Read full PDF)

Greek drug-maker debuts at premium.
Financial Review, 10 June 2004.

Genepharm Australasia became Australia's fourth listed generic pharmaceuticals player on Thursday when its shares made their stockmarket debut at a premium of more than 30 per cent. Shares in Genepharm Australasia opened at 11am (AEST) at 66¢, or 32 per cent above their issue price of 50¢.The shares eased to 60¢ by midday, when about $250,000 worth of scrip had changed hands. (Read full PDF)

Thursday Stockwatch: Closing Report.
Financial Review, 10 June 2004.

Shares in Genepharm Australasia opened at 11.00 am (AEST) at 66¢, or 32 per cent above their issue price of 50¢. The shares closed on their low at 59¢, following turnover of just over 1 million shares. (Read full PDF)

Genepharm to close IPO.
Herald Sun, 7 June 2004.

Investor enthusiasm for the growing generic pharmaceutical market has caused new entrant Genepharm Australasia to close its IPO early. Genepharm closed its subscription for $12 million worth of 50¢ shares last Monday, almost two weeks early. (Read full PDF)

Genepharm seeks $12m.
Financial Review, 25 May 2004.

Australia’s burgeoning generic pharmaceuticals industry is poised to gain a fourth listed player when shares in Genepharm Australasia begin trading on the Australian Stock Exchange next month. Genepharm Australasia is seeking to raise up to $12 million through an initial public offering. (Read full PDF)

Genepharm seeks $12m.
Financial Review, 25 May 2004.

Australia’s burgeoning generic pharmaceuticals industry is poised to gain a fourth listed player when shares in Genepharm Australasia begin trading on the Australian Stock Exchange next month. Genepharm Australasia is seeking to raise up to $12 million through an initial public offering. (Read full PDF)